F-18-fluorothymidine - National Cancer Institute
Alternative Names: 18-F-fluorothymidine; 18F-FLT - National Cancer Institute; 18F-fluorothymidine - National Cancer Institute; 3'-deoxy-3'-[18F] Fluorothymidine PET/CT scanning - National Cancer Institute; F-18-FLT; Fluorine-18 3'-Deoxy-3'-Fluorothymidine (F-18-FLT) - National Cancer InstituteLatest Information Update: 02 Oct 2021
At a glance
- Originator National Cancer Institute (USA)
- Developer National Cancer Institute (USA); Radboud-University-Nijmegen-Medical-Centre; University of Washington
- Class Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Breast cancer
- Phase I/II Glioma
- No development reported Cancer metastases
Most Recent Events
- 25 Aug 2015 Clinical development for Glioma (diagnosis) is ongoing in the USA
- 25 Aug 2015 F-18-fluorothymidine is still in phase II trials for Breast cancer (Diagnosis) in the USA
- 03 Feb 2014 Case Comprehensive Cancer Center and National Cancer Institute plan a clinical trial for Solid tumours (diagnosis) in USA (NCT02055586)